Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
SAN DIEGO, April 20, 2017 -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
| Conference Call Information | |
| Date: | Thursday, May 4, 2017 |
| Time: | 4:30 p.m. ET |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) |
| Confirmation code: | 10209780 |
| Live webcast: | www.retrophin.com in the "Events & Presentations" section of the "Investors" page |
A replay of the call will be available from 7:30 p.m. ET, May 4, 2017 to 7:30 p.m. ET, May 11, 2017. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 10209780.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage candidates targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products, Thiola®, Cholbam®, and Chenodal®.
Contact: Chris Cline, CFA Vice President, Investor Relations & Corporate Communications 646-564-3680 [email protected]
